RecruitingNCT04834869

COVID-19 Vaccines Safety Tracking (CoVaST)

COVID-19 Vaccines Safety Tracking: Global Consortium Study

Sponsor

Masaryk University

Enrollment

30,000 participants

Start Date

Apr 1, 2021

Study Type

OBSERVATIONAL

Conditions

Adverse Reaction to Vaccine COVID19 Vaccine

Summary

This project aims to monitor the side effects of COVID-19 vaccines worldwide actively. The primary objectives of the project include a) to estimate the prevalence of each local and systemic side effect of each COVID-19 vaccine among healthcare workers (HCW), old adults over +65 (OA), and schoolteachers (ST); b) to evaluate the potential demographic and medical risk factors for side effects frequency and intensity; c) to evaluate the long-term consequences of COVID-19 vaccines. The secondary objectives include a) to evaluate the relative safety of COVID-19 vaccines compared to each other; b) to evaluate the impact of palliative drugs used by the recently vaccinated individuals on their short-term side effects resolution.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

HCW, OA and ST who received COVID-19 vaccine.
Participating subjects should be at least 18-year-old and able to give their informed consent independently.

Exclusion Criteria1

Non HCW, OA and ST who received the COVID-19.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBNT162b2

Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)

BIOLOGICALmRNA-1273

Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)

BIOLOGICALAZD1222

Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)

BIOLOGICALCoronaVac

Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)

BIOLOGICALSinopharm

Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine

BIOLOGICALGam-COVID-Vac

Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)

BIOLOGICALJNJ-78436735

Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)

BIOLOGICALCVnCoV

Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)

BIOLOGICALNVX-CoV2373

Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)

BIOLOGICALBBV152

Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)

Locations(14)

American College of Physicians

Philadelphia, Pennsylvania, United States

McMaster University

Hamilton, Ontario, Canada

University of Split

Split, Croatia

Masaryk University

Brno, Czechia

University of Tartu

Tartu, Estonia

Jimma University

Jimma, Ethiopia

Justus-Liebig University Giessen

Giessen, Germany

University of Ghana

Accra, Ghana

Sinaloa's Pediatric Hospital

Culiacán, Mexico

Medical University of Silesia

Katowice, Poland

Nursing School of Coimbra

Coimbra, Portugal

Irkutsk Scientific Center of Siberian Branch of Russian Academy of Sciences

Irkutsk, Russia

University of Belgrade

Belgrade, Serbia

University of Ljubljana

Ljubljana, Slovenia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04834869